The aims of the current study were to examine the efflicacy of acetylcholine (ACh) to mimic ischemic preconditioning in dogs and to determine the role of nitric oxide (NO), muscarinic receptors, and ATP-sensitive K' (KATP) channels in mediating its effects. Barbital-anesthetized open-chest dogs were subjected to 60 minutes of left anterior descending coronary artery (LAD) occlusion followed by 4 hours of reperfusion. Preconditioning was elicited by 10 minutes of LAD occlusion followed by 10 minutes of reperfusion before the 60-minute occlusion period. ACh (3 or 10 gg/min) or an equivalent volume of saline was infused into the LAD for 10 minutes, followed by a 10-minute drug-free period before the 60-minute ischemic insult. In other groups, the specific NO synthesis inhibitor NG_monomethyl-Larginine (L-NMMA, 4 mg/min), the muscarinic receptor antagonist-NO synthesis inhibitor nitro-Larginine methyl ester (L-NAME, 3 mg/min), or the specific KATP channel blocker 5-hydroxydecanoate (5-HD, 3 mg/min) was infused with ACh into the LAD for 10 minutes. The infusion of L-NAME, L-NMMA, or 5-HD was started 2 minutes before ACh infusion. Transmural myocardial blood flow was measured at 5 minutes of occlusion, and infarct size was determined by triphenyltetrazolium staining and expressed as a percentage of the area at risk. There were no significant differences in collateral blood flow or the area at risk between groups. Preconditioning produced a marked reduction (P<.05) in infarct size (6.2±3.0%o versus 26.1±5.7% in the control group). Two doses of ACh (3 and 10 ,ug/min) also resulted in a marked dose-dependent decrease in infarct size (14.4±5.0%o and 10.6±3.1%, respectively) similar to that observed with preconditioning. Simultaneous treatment with either L-NAME or 5-HD completely abolished the protective effects of the high dose (10 ,ug/min) of ACh (25.6+3.1% and 27.0+3.3%, respectively), whereas treatment with L-NMMA had no effect on ACh-induced infarct size reduction.
I schemic preconditioning is an endogenous protective mechanism in which brief periods of myocardial ischemia and reperfusion render the myocardium resistant to a subsequent more sustained ischemic insult.1 This phenomenon has been shown to occur in a variety of animal species including dogs, rabbits, pigs, and rats.2 Since Murry et all described this phenomenon in 1986, numerous studies have been performed to elucidate the mechanism of preconditioning2; however, its cellular basis is still not fully understood.
Acetylcholine (ACh) is the major neurotransmitter found in parasympathetic nerve terminals, and its effects on cardiac function are generally inhibitory via activation of myocardial muscarinic receptors. 3 Stimulation of muscarinic receptors on the vascular endothelium has also been shown to result in the release of nitric oxide, which produces coronary vasodilation and a resultant selective increase in subendocardial blood flow.34
More recently, Vegh et al' have shown the involvement of the L-arginine nitric oxide pathway in the antiarrhythmic effect of ischemic preconditioning in dogs, and Liu and Downey6 have found that ACh mimics the effects of preconditioning to reduce infarct size in rabbits. Balligand et al have also shown that an endogenous nitric oxide synthase pathway exists in isolated myocytes, which regulates the negative chronotropic effects of muscarinic receptor stimulation. Taken together, these results suggest a possible cardioprotective role that is produced by stimulation of muscarinic receptors located on vascular endothelial cells or cardiac myocytes and may be mediated via nitric oxide release. Therefore, the principal objectives of the present study were to determine if ACh mimics the effect of preconditioning in dogs in a dose-related manner and to test whether the muscarinic receptor and nitric oxide mediate this effect.
Finally, recent results from our laboratory with glibenclamide indicate that opening ATP-sensitive K' (KATP) channels is a possible mechanism involved in the actions of ACh to produce ischemic preconditioning in dogs.8 Therefore, the present study was also designed to further determine if the KATP channel is an important component of the coupling mechanism by which ACh mimics preconditioning. For this purpose, we administered the specific KATP channel blocker 5-hydroxydecanoate (5-HD)9-11 simultaneously with ACh in anesthetized dogs. 5-HD was used because this agent is thought to selectively compete with ATP at its binding site within the KATP channel and is thought to be a more specific inhibitor of this channel than glibenclamide, which is thought to bind at a site in the membrane separate from the KATP channel."
Materials and Methods General Preparation of Dogs
Adult mongrel dogs of either sex, weighing 19 to 25 kg, were fasted overnight, anesthetized with the combination of sodium barbital (200 mg/kg IV) and sodium pentobarbital (15 mg/kg IV), and ventilated by a respirator (model 607, Harvard Apparatus, South Natick, Mass) with room air supplemented with 100% oxygen. Atelectasis was prevented by maintaining an expiratory pressure of 5 to 7 cm H20 with a trap. Arterial blood pH, Po2, and Pco2 were monitored at selected intervals by an automatic blood gas system (model AVL 995, AVL Scientific Corp, Roswell, Ga) and maintained within a normal physiological range (pH 7.35 to 7.45; Po2, 80 to 120; and Pco2, 25 to 40) by adjusting the respiratory rate and oxygen flow and by intravenous infusion of 1.5% sodium bicarbonate when necessary. Body temperature was maintained at 38+± C by using a heating pad.
Aortic blood pressure and left ventricular systolic and end-diastolic pressure were measured by using a double pressure transducer-tipped catheter (Millar PC 771), which was inserted into the aorta and left ventricle via the left carotid artery. Left ventricular dP/dt was determined by electronic differentiation of the left ventricular pressure pulse. The right femoral vein and artery were cannulated for drug administration and for withdrawal of a reference blood flow sample used in the determination of myocardial tissue blood flow.
A left thoracotomy was performed at the fifth intercostal space, the lung was retracted, the pericardium was incised, and the heart was suspended in a cradle. A 1.0-to 1.5-cm segment of the left anterior descending coronary artery (LAD) was dissected from surrounding tissue distal to the first diagonal branch, and a calibrated electromagnetic flow probe (Statham SP 7515) was placed around the vessel. A flowmeter (Statham 2202) was used to measure coronary blood flow, and a micrometer-driven mechanical occluder was placed distal to the flow probe. The occluder was used to zero the flow probe (the LAD was occluded for 10 seconds) 20 to occlude the artery. If the basal heart rate was below 150 beats per minute, the heart was paced at that rate with rectangular 4-millisecond pulses and a voltage that was twice threshold via bipolar electrodes sutured to the left atrial appendage. Pacing was not performed in the few animals with initial rates above 150 beats per minute. Heart rate, hemodynamics, and LAD blood flow were monitored and recorded by a polygraph (model 7, Grass Instrument Co, Quincy, Mass) throughout the experiment. The left atrial appendage was cannulated for radioactive microsphere injection, and the right femoral artery was cannulated for withdrawal of a reference blood flow sample used for the measurement of myocardial tissue blood flow. The right femoral vein was cannulated for drug administration. A small catheter with a needle (30 gauge) bent at 90°was inserted into the LAD distal to the flow probe and occluder for intracoronary drug infusions.
Chemicals
ACh 
Experimental Design
Eight groups of animals were studied to determine whether ACh could mimic ischemic preconditioning and whether muscarinic receptors, nitric oxide, and KATP channels were involved (Fig 1) . Dogs in nonpreconditioned groups (series 1 and 3 through 8) were subjected to 60 minutes of LAD occlusion followed by 4 hours of reperfusion, whereas preconditioned dogs (series 2) received a single 10-minute occlusion followed by 10 minutes of reperfusion before being subjected to the same protocol used in the nonpreconditioned groups. In nonpreconditioned dogs (series 1 and 3 through 8), saline (series 1), ACh (3 or 10 ,ug/min, series 3 and 4), L-NAME (3 mg/min, series 5), L-NAME+ACh (3 mg/min and 10 g.tg/min, respectively; series 6), L-NMMA+ACh (4 mg/ min and 10 ,ug/min, respectively; series 7), or 5-HD+ACh (3 mg/min and 10 ,ug/min, respectively; series 8) was infused into the LAD at a rate of 1 mL/min for 10 minutes instead of the 10-minute occlusion period used in preconditioned dogs. Doses of L-NAME and L-NMMA were chosen on the basis of preliminary results obtained in our laboratory (n=3) in which these compounds were shown to almost completely inhibit vasodilator responses to ACh (1 to 10 ,tg/min) and bradykinin (1 to 10 ,g/min), two endothelium-dependent vasodilators (Fig 2) .12 L-NMMA and L-NAME were given 2 minutes before and throughout the infusion of ACh (1 to 10 gtig/min) or bradykinin (1 to 10 ,ug/min). ACh and bradykinin (10 gg/min) produced marked increases in coronary blood flow before L-NMMA or L-NAME (3 to 4 mg/min) of approximately 45 to 55 mL/min; however, the responses after blockade of nitric oxide synthase were only 1 to 10 mL/min. Intracoronary doses of ACh and 5 -HD were chosen on the basis of previous studies from this laboratory. 4, 8 Infarct Size Determination After 4 hours of reperfusion, the LAD was reocminutes before the initial coronary occlusion and later cluded and cannulated just distal to the occlusion site. Subsequently, 10 mL saline and 10 mL patent blue dye were injected at equal pressures into the LAD and left atrium, respectively, to determine the anatomic area at risk and the nonischemic area. The heart was then immediately fibrillated, removed, and sliced into serial transverse sections 6 to 7 mm in width. The nonstained ischemic area was separated from the blue-stained normal area, and the two regions were incubated at 37°C for 20 to 30 minutes in 1% 2,3,5-triphenyltetrazolium chloride (TTC) in 0.1 mol/L phosphate buffer adjusted to pH 7.4. The TTC stains the noninfarcted myocardium a brick-red color, indicating the presence of a formazin precipitate that results from the reduction of TTC by dehydrogenase enzymes present in viable tissue. After storage overnight in 10% formaldehyde, infarcted and noninfarcted tissues within the area at risk were carefully separated and weighed. Infarct size was expressed as a percentage of the area at risk (infarct size/area at risk).
Regional Myocardial Blood Flow Measurement
Regional myocardial tissue blood flow of the normal and ischemic regions was measured by the radioactive microsphere technique as previously described in this laboratory. 13 
Criteria for Exclusion
To ensure that all animals included in data analysis were healthy and exposed to a similar extent of ischemia, the following criteria were used to exclude unsatisfactory dogs: (1) subendocardial collateral flow greater than 0.15 mL.min-'-g-, (2) heart rate greater than 160 beats per minute, and (3) more than three consecutive attempts required to convert ventricular fibrillation with low-energy DC pulses applied directly to the heart.
Statistical Analysis
All values are expressed as mean+SEM. Differences between groups in hemodynamics, blood pH, myocardial collateral blood flow, and infarct size were compared using a two-factor ANOVA with repeated measures and Fisher's least significant difference test. The incidence of ventricular fibrillation was analyzed by Fisher's exact test. Linear regression analysis was also performed to determine the relation between transmural collateral blood flow and infarct size expressed as a percentage of the area at risk. Differences in regression lines between groups were compared by ANCOVA. Differences between groups were considered significant at P<.05.
Results

Mortality and Exclusions
Sixty-seven dogs were randomly assigned to one of eight groups: control dogs (group 1), preconditioned dogs (group 2), ACh-treated dogs (groups 3 and 4), L-NAME-treated dogs (group 5), L-NAME+ACh-treated dogs (group 6), L-NMMA+ACh-treated dogs (group 7), and 5-HD+ACh-treated dogs (group 8). Six dogs were excluded because subendocardial collateral blood flow was greater than 0.15 mL* minm g`(one each in groups 1, 2, 6, and 8; two in group 3). Thus, 61 dogs completed the protocol satisfactorily and were used in data analysis (n=9 for the control group, n= 10 for the preconditioned group, n=8 for L-NAMEtreated group, n=6 for 3 ,ug/min ACh-treated group, and n=7 for the other groups).
Incidence of Ventricular Fibrillation
All animals developed arrhythmias during the experiment, and 35 of the 61 dogs progressed to ventricular fibrillation at least once. The incidence of ventricular fibrillation was markedly lower (P<.05) in preconditioned group (1 of 10 dogs) and 10 ,ug/min ACh-treated group (0 of 7 dogs) as compared with those in the saline-treated group (8 of 9 dogs). There were no significant differences between the saline-treated control group and the other groups (3 of 6 dogs treated with 3 ,ug/min ACh, 6 of 8 L-NAME-treated dogs, 6 of 7 L-NAME+ACh-treated dogs, 4 of 7 L-NMMA+ACh-treated dogs, and 7 of 7 5-HD+ACh-treated dogs). Hemodynamics Heart rate, mean aortic blood pressure, the ratepressure product, left ventricular dP/dt, and LAD blood flow were monitored throughout the experiment, and the values at baseline, immediately before the prolonged occlusion period, at 30 minutes of occlusion, and at 1 and 4 hours of reperfusion for all series are summarized in Table 1 . Hemodynamics were not significantly different between the control group and the other groups throughout the experiment, except that mean aortic blood pressure and rate-pressure product were significantly higher in the two L-NAME-treated groups immediately before the prolonged occlusion period and at 30 minutes of occlusion. LAD blood flow during the 10-minute drug infusion was also markedly higher in groups treated with either dose of ACh (3 ,ug/min, 71±8 mL/min; 10 ,ug/min, 81+6 mL/min) or 5-HD+ACh (78±9 mL/min) than that in the nonpreconditioned saline-treated control group (38±+ 7 mL/ min). The increase in LAD blood flow produced by 10 ,ug/min ACh infusion (43±+6 mL/min increase) was markedly reduced by treatment with L-NAME (7+3 mL/min increase, P<.05) or L-NMMA (10+4 mL/min increase, P<.05) but not affected by treatment with 5-HD (40±7 mL/min increase).
Infarct Size and Area at Risk
The anatomic area at risk expressed as a percentage of the left ventricle was not significantly different between Fig 3A) . Furthermore, treatment with L-NAME did not affect the infarct size (19.6±3.1%) by itself; however, it completely blocked the protective effects of ACh (25.6±3.1%). In contrast, L-NMMA had no effects on ACh-induced protection (13.6±3.8%, Fig 3B) . In addition, treatment with 5-HD totally abolished the ACh-induced protective effect (27.0±3.3%, Fig 3C) .
Figs 4 and 5 demonstrate the relation between infarct size (infarct size/area at risk) and transmural collateral blood flow to the ischemic region at 5 minutes of occlusion. An inverse relation was found between these two parameters in all groups. The regression lines in the preconditioned group and the groups treated with ACh were shifted downward and had a flatter slope (Fig 4) . The regression lines for the groups treated with L-NAME+ACh or S-HD+ACh (Fig SB and SC) were shifted back to that in the nonpreconditioned saline-treated control group; however, treatment with L-NMMA did not affect the regression line for the ACh-treated group (Fig 5A) . These results indicate that, at any given transmural collateral flow, infarct size would be expected to be smaller in the preconditioned group, the ACh-treated groups, and the L-NMMA+ACh-treated group.
Regional Myocardial Blood Flow
Transmural myocardial blood flow data in the ischemic (LAD) region are shown in Table 2 . There were no significant differences between groups in blood flow to any layers of the ischemic myocardium at S and 30 minutes of occlusion and at the end of 4 hours of reperfusion. These data indicate that all groups of animals were subjected to equivalent degrees of ischemia. The subendocardial/subepicardial myocardial blood flow ratio was not significantly different between the control group and the other groups. No significant differences were observed among groups in the nonischemic region.
Discussion
The major findings of the present study are that (1) a 10-minute intracoronary infusion of ACh (3 or 10 ,ug/min) produces a dose-related reduction in myocardial infarct size, with the higher dose (10 jug/min) producing a reduction similar to that of 10 minutes of ischemic preconditioning in dogs, and (2) ischemic insult (6.2+3.0% versus 26.1±+5.7%). Subsequently, intracoronary infusion of ACh (3 or 10 gg/min) for 10 minutes, instead of 10 minutes of occlusion (preconditioning), produced a dose-dependent reduction in infarct size (14.4±5.0% and 10.6+3.1%, respectively).
The dose of 10 ,tg/min ACh reduced infarct size to the same extent as ischemic preconditioning, similar to previous results obtained in our laboratory and reported by Thornton et effects of preconditioning and ACh to limit myocardial necrosis, we also observed that the incidence of ventricular fibrillation was significantly lower in the preconditioned and high-dose ACh-treated groups than that observed in saline-treated and 5 -HD-treated animals. In agreement, Shiki and Hearse15 showed that, after a short period of regional ischemia, premature ventricular contractions, tachycardia, and fibrillation were reduced during reperfusion in anesthetized rats that were previously subjected to brief periods of ischemic preconditioning. Thus, although the present results suggest that preconditioning and ACh appear to exert an antifibrillatory channel activation. It is also important to note that systemic hemodynamics, risk area, and myocardial collateral blood flow were not affected by ACh throughout the experiment, and these observations suggest that ACh exerts its salutary effect via a direct action on the heart. A marked increase in LAD blood flow was observed during the infusion of ACh. Since increasing coronary blood flow may attenuate ischemia/reperfusion injury,17 particularly during reperfusion, it is possible that the preconditioning effects mimicked by ACh might be attributed to an increase in coronary blood flow. However, this is not likely because (1) the increase in coronary blood flow was transient and returned to baseline levels before the 60-minute LAD occlusion period, (2) treatment with L-NMMA markedly attenuated the increase in LAD blood flow induced by ACh infusion but did not antagonize the protective effects of ACh, and (3) administration of the specific KATP channel blocker 5-HD did not reduce the effects of ACh on coronary blood flow but totally abolished the reduction in infarct size and the antifibrillatory effect produced by ACh. Taken together, these data suggest that ACh mimics the protective effects of preconditioning via a direct receptor-mediated mechanism in the heart, although the cellular mechanisms by which it attenuates ischemia/reperfusion injury are not clear.
Furthermore, we observed that the administration of L-NAME did not affect infarct size by itself but completely abolished the beneficial effects of ACh. Although L-NAME is a specific inhibitor of nitric oxide synthesis, it has also been shown to selectively block muscarinic receptors.12 These results suggest that ACh mimics the protective effects of preconditioning via the release of nitric oxide, the blockade of muscarinic receptors, or both. However, since we found that treatment with L-NMMA, another potent nitric oxide synthase inhibitor,18 which lacks muscarinic receptor antagonist properties,12 did not affect the cardioprotective effect of ACh, it is most likely that L-NAME abolished the preconditioning effect of ACh via blockade of myocardial muscarinic receptors and not via a nitric oxide-linked pathway. On the other hand, several studies'9 20 have shown that L-NAME is 10 to 70 times more potent than L-NMMA in blocking nitric oxide synthase; therefore, it is possible that the dose of L-NMMA used in the present study was insufficient to block the AChinduced cardioprotection via nitric oxide synthase inhibition. However, since the vasodilator responses to both ACh and bradykinin were completely blocked by 4 mg/min L-NMMIA, it KATP channels via the M2 muscarinic receptor and a Gi protein, hence, mimicking the effects of ischemic preconditioning. On the other hand, it should be noted that the mode and dose of ACh administration in the present study are artificial and are only meant to demonstrate a mechanism, since it is unlikely that ACh released from parasympathetic nerves is important in ischemic preconditioning in vivo because vagal innervation of the ventricle is sparse in dogs.
Finally, a selective increase in subendocardial blood flow was observed during stimulation of muscarinic receptors in a previous study performed in our laboratory. 4 Although subendocardial blood flow was not measured during the period of ACh infusion in the present study, the subendocardial to subepicardial myocardial blood flow ratio was not significantly different between the control group and the other groups during the occlusion and reperfusion periods. These results suggest that ACh-induced myocardial blood flow redistribution is most likely transient and has probably disappeared before the prolonged occlusion and subsequent reperfusion period. Therefore, it seems unlikely that an ACh-induced increase in subendocardial blood flow is responsible for the cardioprotection produced by ACh.
In conclusion, the results of the present study suggest that stimulation of M2 muscarinic receptors and activation of myocardial KATP channels may be a crucial cellular mechanism by which ACh and preconditioning protect against ischemia/reperfusion injury. The present results also provide evidence that the L-argininenitric oxide or a related pathway is not involved in the mechanism by which ACh mimics preconditioning.
